BioXcel Therapeutics Establishes Immuno-Oncology Clinical Advisory Board to Advance BXCL701 Development
22 août 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Aug. 22, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
08 août 2018 16h01 HE
|
BioXcel Therapeutics, Inc.
Clinical programs in neuroscience (BXCL501) and immuno-oncology (BXCL701) on track Company strengthens business operations and infrastructure NEW HAVEN, Conn., Aug. 08, 2018 (GLOBE NEWSWIRE) --...
BioXcel Therapeutics Strengthens Leadership Team with Industry Veteran Michael De Vivo Ph.D. as Vice President, Neuroscience
07 août 2018 07h02 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Aug. 07, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics to Host Second Quarter 2018 Financial Results and Business Update
02 août 2018 16h05 HE
|
BioXcel Therapeutics, Inc.
Conference call scheduled on August 8, 2018 at 4:30 PM ET NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical...
BioXcel Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference
02 août 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., Aug. 02, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Enhances Leadership with Appointment of Vikas Sharma, Ph.D. as Vice President of Business Development
31 juil. 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., July 31, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal
24 juil. 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
Nature Medicine article expands upon mechanistic findings and presents DPP8/9 inhibition as potential treatment for various cancer types BXCL701 being developed for two rare malignancies: pancreatic...
BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501
10 juil. 2018 08h00 HE
|
BioXcel Therapeutics, Inc.
NEW HAVEN, Conn., July 10, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence...
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development
27 juin 2018 16h01 HE
|
BioXcel Therapeutics, Inc.
Optimal exposure levels for developing BXCL501 sublingual thin film identified Results support clinical evaluation of dexmedetomidine in acute treatment of agitation resulting from neuropsychiatric...
BioXcel Therapeutics Added to Russell Microcap® Index
26 juin 2018 08h30 HE
|
BioXcel Therapeutics, Inc.
BRANFORD, Conn., June 26, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to...